0001625010-15-000005.txt : 20150126 0001625010-15-000005.hdr.sgml : 20150126 20150126120628 ACCESSION NUMBER: 0001625010-15-000005 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150126 DATE AS OF CHANGE: 20150126 EFFECTIVENESS DATE: 20150126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348649 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-232838 FILM NUMBER: 15547548 BUSINESS ADDRESS: STREET 1: 2520 MERIDIAN PARKWAY STREET 2: SUITE 400 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-806-4304 MAIL ADDRESS: STREET 1: 2520 MERIDIAN PARKWAY STREET 2: SUITE 400 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc DATE OF NAME CHANGE: 20060104 D 1 primary_doc.xml X0707 D LIVE 0001348649 CoLucid Pharmaceuticals, Inc. 2520 MERIDIAN PARKWAY SUITE 400 DURHAM NC NORTH CAROLINA 27713 919-806-4304 DELAWARE Colucid Pharmaceuticals Inc. Colucid Pharmaceuticals Inc Corporation true Arthur M. Pappas Pappas Ventures, 2520 Meridian Parkway Suite 400 Durham NC NORTH CAROLINA 27713 Executive Officer Director Mathers P. Thomas 2520 Meridian Parkway Suite 400 Durham NC NORTH CAROLINA 27709 Executive Officer Director Jesse I. Treu One Palmer Square Suite 515 Princeton NJ NEW JERSEY 08542 Director Richard J. Markham 47 Hulfish Street Suite 310 Princeton NJ NEW JERSEY 08542 Director Timothy C. Gupton 1500 Sunday Drive Suite 300 Raleigh NC NORTH CAROLINA 27607 Executive Officer Nadia Rupniak 2520 Meridian Parkway Suite 400 Durham NC NORTH CAROLINA 27713 Executive Officer Bernice Kuca 2520 Meridian Parkway Suite 400 Durham NC NORTH CAROLINA 27713 Executive Officer Martin Edwards Novo A/S Tuborg Havnevej 19 Hellerup G7 DENMARK DK-2900 Director Luc Marengere TVM, 2 Place Alexis Nihon, Suite 902 3500 Blvd De Maisonneuve West Westmount A8 QUEBEC, CANADA H3Z 3CI Director Pharmaceuticals No Revenues 06b false 2015-01-12 false true true New Series C Preferred Stock, and additional shares of Series A Preferred Stock and Series B Preferred Stock false 0 37100000 37100000 0 Includes conversion of indebtedness. false 11 0 0 0 No proceeds are proposed to be used for payment to such persons other than ordinary salary expenses that may be paid out of working capital. false CoLucid Pharmaceuticals, Inc. /s/ Timothy C. Gupton Timothy C. Gupton CFO 2015-01-23